Daniel Iosifescu
Professor of Psychiatry
Data updated
Research Footprint
Daniel Iosifescu appears in 12 tracked papers (2012–2022), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (1200 citations).
Frequent co-authors: James Murrough, Sanjay Mathew and Dennis Charney.
Background & Research
Daniel V. Iosifescu is a clinician‑researcher in psychiatry whose work focuses on rapid‑acting antidepressant treatments and the biological mechanisms underlying treatment‑resistant mood disorders. He has played a central role in multi‑site randomized controlled trials evaluating the antidepressant efficacy of ketamine in treatment‑resistant major depressive disorder, and in secondary studies that examine differential effects in anxious versus non‑anxious depression. His clinical trial work includes systematic assessment of symptomatic outcomes alongside careful characterisation of cognitive effects and safety profiles.
In parallel with clinical trials, Iosifescu has contributed to translational investigations probing neural and peripheral biomarkers of response. His publications include studies of ketamine's modulation of neural responses to emotional perception, neurocognitive sequelae and their relationship to antidepressant benefit, and altered peripheral immune signatures that correlate with and may predict treatment outcome. Collectively his work aims to refine patient selection, clarify mechanisms of action for rapid‑acting therapies, and inform safer, more personalised approaches to treating refractory mood disorders.
Key Impact
Noted for clinical and translational research on ketamine for treatment‑resistant depression, integrating neurocognitive, neuroimaging and immunological biomarkers to predict and understand treatment response.
Collaboration Network
25 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Daniel Iosifescu is associated with.
New York University
academicThe Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.
View stakeholder →Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.
View stakeholder →Massachusetts General Hospital
hospitalThe Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →Mount Sinai
hospitalThe Center for Psychedelic Psychotherapy and Trauma Research located at Mount Sinai and the James J. Peters Department of Veterans Affairs examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Parsons Research Center for Psychedelic Healing has also recently opened at the Icahn School of Medicine at Mount Sinai.
View stakeholder →